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 After many years of lack of interest in the atrium by clinical cardiologists, the evidence 
of increased morbidity and mortality in patients with atrial fibrillation (AF) relocated the 
atrium to a central position in cardiology more than 2 decades ago.1 First came the studies 
showing improved outcome with the use of anticoagulants; later, the ever-lasting controversy 
on rate vs rhythm control; and at present, new imaging techniques and new therapeutic tools 
to better define atrial remodeling and improve therapy.   
Despite recent advances, the clinical classification of AF based on the traditional 3 
categories proposed by Gallagher and Camm in 19972 (paroxysmal, persistent and permanent) 
has remained the cornerstone for the management of AF with few modifications, such as the 
addition of “long-standing AF” to define patients with continuous AF for more than one year as 
still susceptible for interventional therapies.3 The classification retains its utility by guiding 
therapy in combination with other considerations such as symptoms and management of 
underlying risk factors.4 However, data on progression from paroxysmal to persistent forms 
are scarce, and little is known about the mechanisms and time frame of the evolution of the 
disease. Persistent forms are associated with a more advanced atrial remodeling (e.g., larger 
size, increased sphericity5 and fibrosis6). 
The long-term follow-up of the AF-CARAF study7 analyzed the probability of 
progression from paroxysmal to persistent AF at 10 years, and the factors associated with this 
evolution. At 10 years after an initial diagnosis of paroxysmal AF in a population with a mean 
age of about 60 years, the probability of progression to persistent forms despite therapeutic 
efforts is about 35%, and about 30% of patients do not survive. Main factors leading to AF 
progression were age, mitral regurgitation, left atrial dilation, aortic stenosis and LV 
hypertrophy.  Interestingly, after taking into account the competing mortality risk, LV 
hypertrophy and aortic stenosis were no longer associated with progression. Of the three 
remaining independent factors, aging is not modifiable and mitral regurgitation, present in a 
minority of patients (24%), may be correctable. Finally, in the AF-CARAF study, the antero-
posterior left atrium (LA) diameter seems to be the most robust and useful information to 
stratify the risk of progression in clinical practice. LA diameter also has been reported as a 
simple and useful measurement to predict ablation success.8 It is becoming apparent that how 
“sick” or remodeled the atrium is will determine the progression from paroxysmal to 
persistent AF. And yet today, we are still using basic and indirect measurements, such as M-
mode antero-posterior diameter of LA, to infer the extent of atrial disease. Moreover, in 
clinical practice the analysis of atrial remodeling is often overlooked, and only begins to gain 
attention after AF is diagnosed. AF should probably be considered a symptom of an underlying 
atrial cardiomyopathy. A recent consensus has proposed a definition of atrial cardiomyopathy 
as follows: “Any complex of structural, architectural, contractile or electrophysiological 
changes affecting the atria with the potential to produce clinically relevant manifestations”.9 
This definition certainly reinforces the concept that AF is frequently a manifestation of an atrial 
cardiomyopathy that has been developing silently for years, long before AF appears. Camm et 
al10 proposed that a new classification of AF should consider a “pre-AF” category of patients 
with a sick atrium who have not yet developed AF. To summarize, what we see as a 
progression from paroxysmal to persistent AF is probably a surrogate for the progression of 
the underlying atrial cardiomyopathy. The analysis of this progression has been plagued by the 
very limited tools available to successfully explore the atrium; therefore, the possibility to deal 
with the underlying atrial cardiomyopathy more efficiently will be strongly related to the 
available tools to explore the atrium. 
There are several ways by which improving the knowledge of the progression of atrial 
disease could help to control it more efficiently in the near future. Nevertheless, these should 
be preceded by a conceptual change, beginning to explore the atrium in the “pre-AF” state, 
whenever a condition that is known to affect the atrium is present but before AF has occurred. 
In that way, an upstream therapy to prevent progression could be started before an 
irreversible remodeling becomes established. A number of new tools are available, or will be in 
the near future, and will eventually help in exploring the atrium. New fibrosis biomarkers such 
as BNP11 and micro-RNA12 could possibly give information about the “atrial status”. On the 
other hand, more sophisticated imaging techniques such as MRI will allow us to measure 
fibrosis6,13 and sphericity5 more efficiently, aimed at detecting atrial cardiomyopathy in its 
early stages. The extent of atrial fibrosis measured with late gadolinium enhancement has 
been shown to predict success after AF ablation,6 and could possibly be used to screen for a 
“pre-AF” status in populations at risk, such as patients with hypertension. Another proposed 
imaging method is the assessment of shape deformation. Recent studies have shown that 
sphericity of the LA has independent predictive value for post-ablation success,5 and is a better 
predictor for stroke than atrial volume.14 New echocardiographic measurements such as strain 
rate are also able to detect atrial disease.15  
In summary, atrial fibrillation is probably the tip of the iceberg. More efficient 
exploration and earlier detection of the presence of silent atrial cardiomyopathy may lead to 
more efficacious prevention of disease progression using upstream therapies and controlling 
causal risk factors more efficiently. 
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